Pediatric severe asthma biologic options expand
Dupilumab, mepolizumab, benralizumab, and tezepelumab paediatric label expansions plus emerging biologic programs are restructuring paediatric severe asthma.
Paediatric severe asthma has been a corticosteroid-dominated category with limited biologic options compared to adult care. Dupilumab paediatric label expansion to age 6, mepolizumab and benralizumab paediatric availability, and tezepelumab paediatric trials are now reshaping severe-asthma options for children. The diagnostic-pathway question (paediatric phenotyping by eosinophil count, FeNO, allergen sensitisation) defines biologic selection.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.